Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
This session of the ISGIO 2025 meeting focused on the transformative impact of targeted and immunological therapy for advanced colorectal and anal cancers. It features talks on using targeted therapy in the frontline setting, fitting immunotherapy along the treatment continuum, and implementing immunotherapy-based treatment for anal squamous cell carcinoma. The session concluded with a panel discussion on targeted therapy in colorectal cancer and management of anal cancer, framed by the presentation of 4 cases.
Registration is also now open for ISGIO 2026, taking place October 2-3, 2026, in Ft Lauderdale, Florida. Click here to learn more.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in GI oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Develop personalized treatment plans for patients with GI cancers based on the latest evidence and practice guidelines
- Evaluate the latest efficacy and safety data for newly approved agents, novel combinations, and novel agents to consider their potential impact on evolving treatment paradigms in GI cancers
- Incorporate novel data to effectively sequence available therapies for optimal outcomes in patients with GI cancers
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here